Want to see HK:9939 full AI Analyst Report?
Top Page
Kintor Pharmaceutical Ltd
(9939)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$2.00
▲(18.34% Upside)
Action:Reiterated
Date:09/27/26
The score is weighed down primarily by weak financial performance—ongoing operating losses, negative gross profit, and continued cash burn alongside a shrinking equity base. Technicals are neutral to slightly improving short-term but remain below key longer-term moving averages, and valuation support is limited due to a negative P/E and no dividend yield data.
Positive Factors
2025 Revenue Rebound
The 2025 revenue rebound and narrowing losses indicate some improvement in operating performance after the severe weakness of 2022–2023. Although profitability remains unproven, better revenue conversion could support future development funding if the improvement persists over coming reporting periods.
Negative Factors
Persistent Unprofitability
Negative gross profit and continuing operating and net losses show that the business has not yet established an economically sustainable operating model. Even with losses narrowing, persistently negative margins limit internally generated funding and make future progress dependent on successful development or financing.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Rebound
The 2025 revenue rebound and narrowing losses indicate some improvement in operating performance after the severe weakness of 2022–2023. Although profitability remains unproven, better revenue conversion could support future development funding if the improvement persists over coming reporting periods.
Read all positive factors
Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$869.86M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth647.17%
EPS Growth-8.86%
CountryHK
Employees122
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding498,660,100
10 Day Avg. Volume663,150
30 Day Avg. Volume1,152,500
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kintor Pharmaceutical Ltd Business Overview & Revenue Model
Company Description
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on a...
How the Company Makes Money
Kintor Pharmaceutical Ltd’s business model is typical of a clinical-stage biopharmaceutical developer: it invests in R&D to advance proprietary drug candidates and seeks to monetize them primarily through (i) out-licensing and collaboration arrang...
Kintor Pharmaceutical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.57M | 32.68M | 5.00M | 0.00 | 0.00 | 34.23M |
| Gross Profit | 9.75M | 8.04M | -4.73M | -67.63M | -21.38M | 34.23M |
| EBITDA | -159.18M | -140.66M | -128.37M | -1.06B | -956.45M | -829.09M |
| Net Income | -189.63M | -200.11M | -155.29M | -1.06B | -954.37M | -842.10M |
Balance Sheet | ||||||
| Total Assets | 318.88M | 340.95M | 515.13M | 869.23M | 2.06B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 31.79M | 34.78M | 148.69M | 455.50M | 875.08M | 1.06B |
| Total Debt | 133.56M | 86.64M | 133.01M | 253.92M | 286.39M | 159.73M |
| Total Liabilities | 209.68M | 158.28M | 221.05M | 411.12M | 559.95M | 412.83M |
| Stockholders Equity | 109.20M | 182.67M | 294.08M | 458.11M | 1.50B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -99.68M | -166.07M | -200.76M | -390.30M | -988.73K | -1.13M |
| Operating Cash Flow | -149.83M | -165.34M | -199.08M | -387.58M | -961.26K | -1.05M |
| Investing Cash Flow | 267.76K | 14.04M | 20.03M | 3.27M | 67.19K | 92.00K |
| Financing Cash Flow | 126.54M | 39.23M | -119.67M | -33.46M | 815.75K | 857.42K |
Kintor Pharmaceutical Ltd Technical Analysis
Negative
1.69
Price Trends
1.79
Negative
2.04
Negative
2.35
Negative
Market Momentum
0.01
Positive
43.92
Neutral
10.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Negative. The current price of 1.69 is below the 20-day moving average (MA) of 1.87, below the 50-day MA of 1.79, and below the 200-day MA of 2.35, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 43.92 is Neutral, neither overbought nor oversold. The STOCH value of 10.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9939.
Kintor Pharmaceutical Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$4.71B | 7.97 | 47.76% | ― | 286.20% | ― | |
52 Neutral | HK$731.93M | -3.38 | -30.93% | ― | -17.22% | -6.13% | |
48 Neutral | HK$7.84B | -42.03 | -10.27% | ― | -31.77% | -177.01% | |
48 Neutral | HK$7.40B | -67.12 | -9.45% | ― | 68.12% | 81.84% | |
45 Neutral | HK$11.25B | -6.76 | -153.78% | ― | 70.26% | -12.79% | |
43 Neutral | HK$869.86M | -3.67 | -129.93% | ― | 647.17% | -8.86% |
* General Sector Average
HK:9939
Kintor Pharmaceutical Ltd
1.76
-0.63
-26.33%
HK:9966
Alphamab Oncology
8.45
-6.87
-44.84%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
6.06
-3.44
-36.21%
HK:1244
3D Medicines, Inc.
2.81
-5.31
-65.41%
HK:2171
CARsgen Therapeutics Holdings Ltd.
12.60
-6.68
-34.65%
HK:6855
Ascentage Pharma Group International
30.74
-47.66
-60.79%
Kintor Pharmaceutical Ltd Corporate Events
Kintor Pharma Reshapes Finance Leadership With New CFO and Process Agent
Sep 21, 2026
Kintor Pharmaceutical Limited announced that chief financial officer and joint company secretary Ming Ming Cheung has resigned, also stepping down as the company’s Hong Kong process agent, effective 21 September 2026. The board emphasized th...
Kintor completes year-long safety trial for whitening ingredient KT-939
Sep 6, 2026
Kintor Pharmaceutical announced the successful completion of a year-long human safety trial for KT-939, its in-house developed tyrosinase inhibitor designed for whitening and freckle-removal cosmetic applications. The open-label study followed 114...
Kintor Pharmaceutical Boosts Revenue on Cosmetics Push but Stays in the Red
Aug 19, 2026
Kintor Pharmaceutical reported a sharp increase in revenue to RMB52.0 million for the six months ended June 30, 2026, up from RMB6.0 million a year earlier, driven mainly by global sales of its new high-end cosmetics brand KOSHINÉ that uses c...
Kintor Pharmaceutical Sets Board Meeting to Approve 2026 Interim Results
Aug 5, 2026
Kintor Pharmaceutical Limited has announced that its board of directors will convene on 19 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also authorize the publication of th...
Kintor Moves to Resolve Going-Concern Audit Issue With KX-826 Commercial Push
Jul 31, 2026
Kintor Pharmaceutical Limited has outlined measures to address a prior auditor’s disclaimer of opinion linked to concerns over its ability to continue as a going concern, focusing on improving operating cash flow, negotiating extended paymen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.